Zepatier is an antiviral drug owned by Merck Sharp Dohme. The drug contains the active ingredients Elbasvir and Grazoprevir and was first authorized for market use on 28 January, 2016. Zepatier holds a total of 2 patents.
The generic version of Zepatier could potentially be released after 04 May, 2031. This release date is likely since Zepatier's last patent (US8871759 - 'Inhibitors of Hepatitis C virus replication') is due to expire on this date.
Zepatier is primarily used for the treatment of patients infected with the Hepatitis C virus. Its active ingredients, Elbasvir and Grazoprevir, work together to inhibit the virus replication, thereby helping to control the infection.